Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modulation of endothelial lipase expression

a technology of endothelial lipase and expression, applied in the field of moduled can solve the problems of no known therapeutic agent which effectively inhibits the synthesis of endothelial lipase, and achieve the effect of modulating the expression of endothelial lipas

Inactive Publication Date: 2007-01-25
IONIS PHARMA INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019] The present invention is directed to compounds, especially nucleic acid and nucleic acid-like oligomers, which are targeted to a nucleic acid encoding endothelial lipase, and which modulate the expression of endothelial lipase. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further provided are methods of screening for modulators of endothelial lipase and methods of modulating the expression of endothelial lipase in cells, tissues or animal

Problems solved by technology

Currently, there are no known therapeutic agents which effectively inhibit the synthesis of endothelial lipase.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of Nucleoside Phosphoramidites

[0107] The following compounds, including amidites and their intermediates were prepared as described in U.S. Pat. No. 6,426,220 and published PCT WO 02 / 36743; 5′-O-Dimethoxytrityl-thymidine intermediate for 5-methyl dC amidite, 5′-O-Dimethoxytrityl-2′-deoxy-5-methylcytidine intermediate for 5-methyl-dC amidite, 5′-O-Dimethoxytrityl-2′-deoxy-N4-benzoyl-5-methylcytidine penultimate intermediate for 5-methyl dC amidite, [5′-O-(4,4′-Dimethoxytriphenylmethyl)-2-deoxy-N4-benzoyl-5-methylcytidin-3-O-yl ]-2-cyanoethyl-N,N-diisopropylphosphoramidite (5-methyl dC amidite), 2′-Fluorodeoxyadenosine, 2′-Fluorodeoxygua 2′-Fluorouridine, 2′-Fluorodeoxycytidine, 2′-O-(2-Methoxyethyl) modified amidites, 2′-O-(2-methoxyethyl)-5-methyluridine intermediate, 5′-O-DMT-2-O-(2-methoxyethyl)-5-methyluridine penultimate intermediate, [5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-5-methyluridin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE T...

example 2

Oligonucleotide and Oligonucleoside Synthesis

[0108] The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

Oligonucleotides: Unsubstituted and substituted phosphodiester (P═O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 394) using standard phosphoramidite chemistry with oxidation by iodine.

[0109] Phosphorothioates (P═S) are synthesized similar to phosphodiester oligonucleotides with the following exceptions: thiation was effected by utilizing a 10% w / v solution of 3,H-1,2-benzodithiole-...

example 3

RNA Synthesis

[0119] In general, RNA synthesis chemistry is based on the selective incorporation of various protecting groups at strategic intermediary reactions. Although one of ordinary skill in the art will understand the use of protecting groups in organic synthesis, a useful class of protecting groups includes silyl ethers. In particular bulky silyl ethers are used to protect the 5′-hydroxyl in combination with an acid-labile orthoester protecting group on the 2′-hydroxyl. This set of protecting groups is then used with standard solid-phase synthesis technology. It is important to lastly remove the acid labile orthoester protecting group after all other synthetic steps. Moreover, the early use of the silyl protecting groups during synthesis ensures facile removal when desired, without undesired deprotection of 2′ hydroxyl.

[0120] Following this procedure for the sequential protection of the 5′-hydroxyl in combination with protection of the 2′-hydroxyl by protecting groups that...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

Compounds, compositions and methods are provided for modulating the expression of endothelial lipase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial lipase. Methods of using these compounds for modulation of endothelial lipase expression and for diagnosis and treatment of disease associated with expression of endothelial lipase are provided.

Description

RELATED APPLICATIONS [0001] This application is a continuation-in-part of U.S. patent application Ser. No. 10 / 319,915, filed Dec. 12, 2002. This application is also a continuation-in-part of U.S. patent application Ser. No. 11 / 036,095, filed Jan. 14, 2005; which is a continuation-in-part of the following U.S. patent applications: Ser. No. 10 / 187,110, filed Jun. 29, 2002; Ser. No. 10 / 303,328, filed Nov. 22, 2002; Ser. No. 10 / 302,028, filed Nov. 21, 2002; Ser. No. 10 / 293,866, filed Nov. 11, 2002; Ser. No. 10 / 316,241, filed Dec. 9, 2002; Ser. No. 10 / 317,401, filed Dec. 11, 2002; Ser. No. 10 / 210,556, filed Jul. 31, 2002; Ser. No. 10 / 210,723, filed Jul. 31, 2002; Ser. No. 10 / 318,389, filed Dec. 11, 2002; Ser. No. 10 / 302,027, filed Nov. 21, 2002; Ser. No. 10 / 300,399, filed Nov. 19, 2002; Ser. No. 10 / 189,429, filed Jul. 3, 2002; Ser. No. 10 / 174,020, filed Jun. 17, 2002; Ser. No. 10 / 177,554, filed Jun. 20, 2002; Ser. No. 10 / 185,035, filed Jun. 28, 2002; Ser. No. 10 / 316,755, filed Dec. 10, 2...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68C07H21/02C07F9/6512C07H21/04C12N15/113
CPCC07H21/00C07H21/04C12N15/1137C12N2310/11C12N2310/315C12N2310/321C12Y301/01003C12N2310/3341C12N2310/341C12N2310/346C12N2310/3525
Inventor DOBIE, KENNETH W.
Owner IONIS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com